呼吸易感性蛋白质组风险评分:多队列研究
本研究基于CARDIA队列30年纵向FEV1数据定义肺功能加速下降轨迹,用蛋白质组学构建呼吸易感性评分,并在UK Biobank和COPDGene中验证其与呼吸疾病和死亡风险的关联。结果显示评分越高,全因死亡、呼吸死亡、新发慢阻肺及呼吸急性加重风险均显著增加。
要点
- 蛋白质组呼吸易感性评分可预测呼吸死亡、新发慢阻肺和急性加重。
- 该评分无需多年肺功能测定即可早期识别高危人群。
- 评分由与肺健康相关的新颖及已知蛋白组成。
核心结论
- 呼吸易感性蛋白质组特征可识别呼吸死亡、新发慢阻肺和呼吸急性加重的高危人群。
研究设计与样本
- 在CARDIA队列中用最多6个时间点、跨度30年的纵向FEV1占预计值百分比识别加速与正常下降轨迹。
- 通过多变量逻辑回归和LASSO回归筛选与加速下降轨迹相关的蛋白适配体,构建呼吸易感性评分。
- 将评分应用于UK Biobank和COPDGene研究,分析其与未来呼吸疾病发病和死亡的关系。
主要发现
- 评分较高与全因死亡独立相关:UKBB HR 1.56(95%CI 1.50-1.61),COPDGene HR 1.75(95%CI 1.63-1.88)。
- 评分较高与呼吸死亡独立相关:UKBB HR 2.39(95%CI 2.16-2.64),COPDGene HR 1.81(95%CI 1.32-2.47)。
- 评分较高与新发慢阻肺相关:UKBB HR 1.84(95%CI 1.71-1.98)。
- 评分较高与新发呼吸急性加重相关:COPDGene OR 1.10(95%CI 1.02-1.19)。
- 评分较高与需住院的急性加重相关:COPDGene OR 1.17(95%CI 1.08-1.27)。
临床怎么用
- 该评分有望在不依赖多年肺功能测定的情况下早期识别呼吸疾病高危人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Accelerated decline in lung function is associated with incident chronic obstructive pulmonary disease (COPD), hospitalization, and death. However, identifying this trajectory with longitudinal spirometry measurements is challenging in clinical practice. Objectives: To determine whether a proteomic risk score trained on accelerated decline in lung function can assess the risk of future respiratory disease and mortality. Methods: In the Coronary Artery Risk Development in Young Adults Study, a population-based cohort starting in young adulthood, longitudinal measurements of FEV1 percent predicted (up to six time points over 30 yr) were used to identify accelerated and normal decline trajectories. Protein aptamers associated with an accelerated decline trajectory were identified with multivariable logistic regression followed by LASSO (least absolute shrinkage and selection operator) regression. The proteomic respiratory susceptibility score was derived on the basis of these circulating proteins and applied to the U.K. Biobank (UKBB) and COPDGene studies to examine associations with future respiratory morbidity and mortality. Measurements and Main Results: Higher susceptibility score was independently associated with all-cause mortality (UKBB hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.50-1.61; COPDGene HR, 1.75 95% CI, 1.63-1.88), respiratory mortality (UKBB HR, 2.39; 95% CI, 2.16-2.64; COPDGene HR, 1.81; 95% CI, 1.32-2.47), incident COPD (UKBB HR, 1.84; 95% CI, 1.71-1.98), incident respiratory exacerbation (COPDGene odds ratio, 1.10; 95% CI, 1.02-1.19), and incident exacerbation requiring hospitalization (COPDGene OR, 1.17; 95% CI, 1.08-1.27). Conclusions: A proteomic signature of increased respiratory susceptibility identifies people at risk of respiratory death, incident COPD, and respiratory exacerbations. This susceptibility score is composed of proteins with well-known and novel associations with lung health and holds promise for the early detection of lung disease without requiring years of spirometry measurements.
引用
- Liu, Perry, Washko, et al. Proteomic Risk Score of Increased Respiratory Susceptibility: A Multicohort Study. Am J Respir Crit Care Med. 2025. PMID: 39254293. doi:10.1164/rccm.202403-0613OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。